ERBB2 and non-small cell lung carcinoma: Our case suggests that advanced NSCLC patients with both EGFR mutation and HER2 amplification may achieve sustained disease control through the combination of almonertinib and pyrotinib, possibly due to the simultaneous inhibition of the EGFR and HER2 signaling pathways.